Highlights

  • Botanix Pharmaceuticals (ASX:BOT) shipped 35,130 Sofdra prescriptions in Q1 FY27.
  • Unaudited quarterly Sofdra net Revenue remained at USD 10.1 million.
  • Operating cash outflow declined to AUD 9.2 million for the September quarter.
  • Quarter-end cash was AUD 24.4 million as cost reductions continued.

Botanix Pharmaceuticals Limited is a commercial dermatology company focused on Sofdra, a prescription topical treatment for primary axillary hyperhidrosis in the United States. Shares in Botanix Pharmaceuticals (ASX:BOT) were quoted at AUD 0.009 on 13 November 2026, a decline of 10.00% for the session. The company’s September-quarter report highlighted increased prescription shipments but unchanged net product revenue, alongside steps to reduce costs and preserve liquidity.

Sofdra Commercial Operations in the United States

For Botanix (ASX:BOT), Sofdra is a 12.45% topical gel containing sofpironium and is the focus of Botanix’s US commercial operations. Sales depend on prescription demand, shipment completion, insurance reimbursement, patient access and deductions between gross sales and the net amount recognised. Its commercial strategy therefore involves more than increasing the number of prescriptions written or shipped; reimbursement processes directly influence the revenue ultimately retained.

Prescription Growth and Commercial Changes

The September 2026 quarter, the first quarter of FY27, recorded 35,130 total prescriptions shipped, compared with 33,358 in the June quarter, an increase of 5.3%. Botanix also reported that shipments across the latest six-month period were approximately 32% above the preceding six months. The sales organisation had been reduced from 50 to 39 personnel by 31 July 2026, making productivity and prescription conversion areas of operational scrutiny.

The company identified prior-authorisation submissions as an area requiring attention. It said lower submission levels had contributed to softer gross-to-net conversion and that corrective steps were implemented. Botanix outlined work to improve submission and approval rates, patient prescription shipments and continuation of treatment. These initiatives are management actions rather than demonstrated future revenue gains.

Quarterly Revenue, Cash Flow and Funding

Unaudited Sofdra net revenue was USD 10.1 million in Q1 FY27, unchanged from the previous quarter despite gross sales rising to USD 49.3 million from USD 46.7 million. Average gross-to-net Yield fell to 21% from 22%. The distinction is material: a greater value of product shipped or billed did not produce a corresponding increase in recognised net sales during the period.

Net operating cash outflow improved 13% to approximately AUD 9.2 million from AUD 10.6 million. Receipts from product sales rose to around AUD 15.2 million from AUD 13.4 million. Cash at 30 September was AUD 24.4 million, compared with AUD 36.6 million at 30 June. The Business therefore remained cash-consuming, notwithstanding improved receipts and lower reported quarterly outflows.

Supply Arrangements and Risks

During October, Botanix disclosed a Manufacturing and Supply agreement with Piramal for an alternative active pharmaceutical ingredient source. It said the arrangement was expected to lower its Cost of Goods Sold by 25% to 40%, although realised savings remain dependent on implementation. The company also described measures targeting materially lower annual operating expenditure following quarter end, and continued to assess strategic and financing alternatives.

Key risks concern reimbursement acceptance, net selling prices, commercial execution after staffing reductions, inventory needs and funding requirements. Patent protection and alternative manufacturing arrangements may influence operations but do not remove these uncertainties. The company’s US exposure also links performance to insurance processes, channel arrangements and the commercial pace of Sofdra adoption.

Key Insights

Botanix Pharmaceuticals (ASX:BOT) reported more prescriptions but no quarter-on-quarter growth in Sofdra net revenue. The contrast between gross sales and net receipts, alongside a declining cash balance, helps explain the emphasis on reimbursement procedures and expenditure controls. Subsequent updates on gross-to-net yield, cash use, manufacturing costs and product Demand will be important measures of whether operational changes translate into financial results.